# US 2008/0305074 A1 · Stem cell factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305074 A1
- Document ID: US20080305074A1
- Status: Published application
- Kind: A1
- Application number: 11/702,389
- Filed: 2007-02-05
- Published: 2008-12-11
- Earliest claimed: 1989-10-16
- Assignees: Amgen Inc.
- Inventors: Krisztina M. Zsebo; Robert A. Bosselman; Sidney V. Suggs; Francis H. Martin
- Web page: https://patentgrep.com/patent/US20080305074A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/00: Drugs for skeletal disorders
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.

## Claims

### Claim at position 1

1-70. (canceled)

### Claim 71

A method of treating a hematopoietic disorder characterized by reduction in bone marrow mass, comprising the step of administering to a human an effective amount of a human stem cell factor (SCF) polypeptide and optionally a pharmaceutically acceptable carrier.

### Claim 72 (depends on 71)

The method of claim 71 wherein the stem cell factor (SCF) polypeptide is selected from the group consisting of amino acids 1-162, 1-164, and 1-165 as set out in-SEQ ID NO: 46, said polypeptide optionally consisting of an N-terminal methionine.

### Claim 73 (depends on 71)

The method of claim 71 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-100, 1-110, 1-120, 1-123, 1-127, 1-130, 1-133, 1-137, 1-141, 1-145, 1-148, 1-152, 1-156, 1-157, 1-158, 1-159, 1-160, 1-161, 1-163, 1-166, 1-168, 1-173, 1-178, 2-164, 2-165, 5-164, 11-164, 1-180, 1-183, 1-185, 1-188, 1-189, 1-220, and 1-248 as set out in SEQ ID NO 61, said polypeptide optionally consisting of an N-terminal methionine.

### Claim 74 (depends on 71)

The method of claim 71 wherein the stem cell factor polypeptide is selected from the group consisting of amino acids 1-152, 1-157, 1-160, 1-161, and 1-220 as set out in SEQ ID NO 63, said polypeptide optionally consisting of an N-terminal methionine.

### Claim 75 (depends on 71)

The method of claim 71 wherein the stem cell factor is covalently conjugated to a water-soluble polymer.

### Claim 76 (depends on 75)

The method of claim 75 wherein the water-soluble polymer is polyethylene glycol.

### Claim 77 (depends on 71)

The method of claim 71 wherein the stem cell factor is SCF1-164 PEG 25.

### Claim 78 (depends on 71)

The method of claim 71 wherein the stem cell factor is SCF1-193.

### Claim 79 (depends on 71)

The method of claim 71 wherein the stem cell factor is co-administered with at least one other cytokine and optionally a pharmaceutically acceptable carrier.

### Claim 80 (depends on 79)

The method of claim 79 wherein one or more cytokines are selected from a group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), Macrophage Colony Stimulating Factor (M-CSF) granulocyte-monocyte colony stimulating factor (GM-CSF), insulin growth factor-1 (IGF-1) and leukemia inhibitory factor (LIF).

### Claim 81 (depends on 80)

The method of claim 80 wherein the cytokine is granulocyte colony stimulating factor (G-CSF).

### Claim 82 (depends on 75)

The method of claim 75 wherein the stem cell factor is co-administered with at least one other cytokine.

### Claim 83 (depends on 82)

The method of claim 82 wherein the cytokine is selected from a group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, erythropoietin (EPO), granulocyte colony stimulating factor (G-CSF), Macrophage Colony Stimulating Factor (M-CSF), granulocyte-monocyte colony stimulating factor (GM-CSF), insulin growth factor-1 (IGF-1), and leukemia inhibitory factor (LIF).

### Claim 84 (depends on 83)

The method of claim 83 wherein the cytokine is granulocyte colony stimulating factor (G-CSF).

### Claim 85 (depends on 71, 75)

The method of claim 71 or 75 wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.

### Claim 86 (depends on 71, 75)

The method of claim 71 or 75 wherein the pharmaceutically acceptable carrier is suitable for pulmonary delivery.

### Claim 87 (depends on 71, 75)

The method of claim 71 or 75 wherein the pharmaceutically acceptable carrier is suitable for nasal delivery.

### Claim 88 (depends on 71)

The method of claim 71 wherein the hematopoietic disorder is selected from the group consisting of aplastic anemia, Diamond-Blackfan anemia (DBA), Fanconi's anemia, dyskeratosis congenita, amegakaryocytic thrombocytopenia, thrombocytopenia with absent radii, congenital agranulocytosis (e.g. Kostmann's syndrome, Shwachman-Diamond syndrome), and idiopathic and cyclic neutropenia.

### Claim 89 (depends on 71)

The method of claim 71 wherein the hematopoietic disorder is aplastic anemia.
